OSLO ,4 January 2023 : The following primary insiders and close associates of primary insiders ofEXACT Therapeutics AS ("Exact-Tx AS") have onJanuary 3, 2023 purchased shares as follows: - Kvåle AS, a close associate of Chief Operating OfficerSvein Kvåle , has purchased 2,500 shares atNOK 12 per share. Following the purchase, Kvåle AS holds 3,024,270 shares in Exact-Tx AS - PAACS Invest AS, a close associate of Board MemberMasha Strømme , has purchased 2,500 shares atNOK 12 per share. Following the purchase, PAACS Invest AS holds 2,691,509 shares in Exact-Tx AS -Anders Wold , Chairman of the Board, has purchased 2,500 shares atNOK 12 per share. Following the purchase, Wold holds 4,914 shares in Exact-Tx AS - Per Walday, Chief Executive Officer, has purchased 2,500 shares atNOK 12 per share. Following the purchase, Walday holds 2,500 shares in Exact-Tx AS and rights to 610,643 shares. -Amir Snapir , Chief Medical Officer, has purchased 2,500 shares atNOK 12 per share. Following the purchase, Snapir holds 2,500 shares in Exact-Tx AS and rights to 60,000 shares -John M. Edminson , Chief Financial Officer, has purchased 2,500 shares atNOK 12 per share. Following the purchase, Edminson holds 2,500 shares in Exact-Tx AS and rights to 30,000 shares This information is subject to the disclosure requirements in Regulation EU 596/2014 (MAR) article 19 number 3 and section 5-12 of theNorwegian Securities Trading Act. Primary insider notifications pursuant to the EU Market Abuse Regulation Article 19 are attached hereto. For more information, please contact: Per Walday, CEO, per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drugtargeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com
Click here for more information
© Oslo Bors ASA, source